アジア太平洋のてんかん治療市場2020-2024

◆英語タイトル:Epilepsy Therapeutic Market in APAC 2020-2024
◆商品コード:IRTNTR44446
◆発行会社(リサーチ会社):Technavio
◆発行日:2020年8月
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、その他アジア太平洋
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、てんかん治療のアジア太平洋市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、製品別分析、顧客状況、地域状況、企業状況、企業分析などの構成でお届けいたします。
【レポートの概要】

Global Epilepsy therapeutic market in APAC 2020-2024Technavio has been monitoring the epilepsy therapeutic market in APAC and it is poised to grow by $ 232.12 mn during 2020-2024 progressing at a CAGR of 3% during the forecast period. Our reports on epilepsy therapeutic market in APAC provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current APAC market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high unmet medical need, increase in patient population and rising awareness. In addition, high unmet medical need is anticipated to boost the growth of the market as well.
The epilepsy therapeutic market in APAC analysis includes product segments.1.
Technavio’s epilepsy therapeutic market in APAC is segmented as below:
By Product
• First-generation epilepsy therapeutics
• Second-generation epilepsy therapeutics
• Third-generation epilepsy therapeutics
By Geographic Landscapes
• Asia
• Rest of APAC
This study identifies the emergence of new-generation AEDs as one of the prime reasons driving the epilepsy therapeutic market in APAC growth during the next few years. Also, reformulation of marketed drugs and AEDs with novel mechanism of action will lead to sizable demand in the market.
“Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our epilepsy therapeutic market in APAC covers the following areas:
• Epilepsy therapeutic market in APAC sizing
• Epilepsy therapeutic market in APAC forecast
• Epilepsy therapeutic market in APAC industry analysis”
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epilepsy therapeutic market in APAC vendors that include Bausch Health Companies Inc., BIAL – PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi, Sunovion Pharmaceuticals Inc., UCB SA, and Zogenix Inc.. Also, the epilepsy therapeutic market in APAC analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/epilepsy-therapeutics-market-in-apac-industry-analysis
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Market characteristics
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o First-generation epilepsy therapeutics – Market size and forecast 2019-2024
o Second-generation epilepsy therapeutics – Market size and forecast 2019-2024
o Third-generation epilepsy therapeutics – Market size and forecast 2019-2024
o Market opportunity by Product
• Customer Landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o Asia – Market size and forecast 2019-2024
o Rest of APAC – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Bausch Health Companies Inc.
o BIAL – PORTELA & CA SA
o GlaxoSmithKline Plc
o Johnson & Johnson
o Novartis AG
o Pfizer Inc.
o Sanofi
o Sunovion Pharmaceuticals Inc.
o UCB SA
o Zogenix Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Parent market
• 8: Market characteristics
• 9: Offerings of vendors included in the market definition
• 10: Market segments
• 11: Global – Market size and forecast 2019 – 2024 ($ million)
• 12: Global market: Year-over-year growth 2019 – 2024 (%)
• 13: Five forces analysis 2019 & 2024
• 14: Bargaining power of buyers
• 15: Bargaining power of suppliers
• 16: Threat of new entrants
• 17: Threat of substitutes
• 18: Threat of rivalry
• 19: Market condition – Five forces 2019
• 20: Product – Market share 2019-2024 (%)
• 21: Comparison by Product
• 22: First-generation epilepsy therapeutics – Market size and forecast 2019-2024 ($ million)
• 23: First-generation epilepsy therapeutics – Year-over-year growth 2019-2024 (%)
• 24: Second-generation epilepsy therapeutics – Market size and forecast 2019-2024 ($ million)
• 25: Second-generation epilepsy therapeutics – Year-over-year growth 2019-2024 (%)
• 26: Third-generation epilepsy therapeutics – Market size and forecast 2019-2024 ($ million)
• 27: Third-generation epilepsy therapeutics – Year-over-year growth 2019-2024 (%)
• 28: Market opportunity by Product
• 29: Customer landscape
• 30: Market share by geography 2019-2024 (%)
• 31: Geographic comparison
• 32: Asia – Market size and forecast 2019-2024 ($ million)
• 33: Asia – Year-over-year growth 2019-2024 (%)
• 34: Rest of APAC – Market size and forecast 2019-2024 ($ million)
• 35: Rest of APAC – Year-over-year growth 2019-2024 (%)
• 36: Key leading countries
• 37: Market opportunity by geography ($ million)
• 38: Impact of drivers and challenges
• 39: Vendor landscape
• 40: Landscape disruption
• 41: Industry risks
• 42: Vendors covered
• 43: Market positioning of vendors
• 44: Bausch Health Companies Inc. – Overview
• 45: Bausch Health Companies Inc. – Business segments
• 46: Bausch Health Companies Inc. – Key offerings
• 47: Bausch Health Companies Inc. – Key customers
• 48: Bausch Health Companies Inc. – Segment focus
• 49: BIAL – PORTELA & CA SA – Overview
• 50: BIAL – PORTELA & CA SA – Product and service
• 51: BIAL – PORTELA & CA SA – Key offerings
• 52: BIAL – PORTELA & CA SA – Key customers
• 53: BIAL – PORTELA & CA SA – Segment focus
• 54: GlaxoSmithKline Plc – Overview
• 55: GlaxoSmithKline Plc – Business segments
• 56: GlaxoSmithKline Plc – Key offerings
• 57: GlaxoSmithKline Plc – Key customers
• 58: GlaxoSmithKline Plc – Segment focus
• 59: Johnson & Johnson – Overview
• 60: Johnson & Johnson – Business segments
• 61: Johnson & Johnson – Key offerings
• 62: Johnson & Johnson – Key customers
• 63: Johnson & Johnson – Segment focus
• 64: Novartis AG – Overview
• 65: Novartis AG – Business segments
• 66: Novartis AG – Key offerings
• 67: Novartis AG – Key customers
• 68: Novartis AG – Segment focus
• 69: Pfizer Inc. – Overview
• 70: Pfizer Inc. – Business segments
• 71: Pfizer Inc. – Key offerings
• 72: Pfizer Inc. – Key customers
• 73: Pfizer Inc. – Segment focus
• 74: Sanofi – Overview
• 75: Sanofi – Business segments
• 76: Sanofi – Key offerings
• 77: Sanofi – Key customers
• 78: Sanofi – Segment focus
• 79: Sunovion Pharmaceuticals Inc. – Overview
• 80: Sunovion Pharmaceuticals Inc. – Product and service
• 81: Sunovion Pharmaceuticals Inc. – Key offerings
• 82: Sunovion Pharmaceuticals Inc. – Key customers
• 83: Sunovion Pharmaceuticals Inc. – Segment focus
• 84: UCB SA – Overview
• 85: UCB SA – Product and service
• 86: UCB SA – Key offerings
• 87: UCB SA – Key customers
• 88: UCB SA – Segment focus
• 89: Zogenix Inc. – Overview
• 90: Zogenix Inc. – Product and service
• 91: Zogenix Inc. – Key offerings
• 92: Zogenix Inc. – Key customers
• 93: Zogenix Inc. – Segment focus
• 94: Currency conversion rates for US$
• 95: Research Methodology
• 96: Validation techniques employed for market sizing
• 97: Information sources
• 98: List of abbreviations



【掲載企業】

Bausch Health Companies Inc., BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi, Sunovion Pharmaceuticals Inc., UCB SA, Zogenix Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アジア太平洋のてんかん治療市場2020-2024]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆